PK

Parveen Kumar

Active Director Director DIN 10084815
DIN 10084815 First appointment Mar 2023 Primary industry Pharma
Unlock full profile Investments · shareholding · contact details
Current companies 1 active board seats
Total affiliations 1 Since Mar 2023
Shareholding value •••• Premium profile

About Parveen Kumar

Data last updated:

Parveen Kumar is a Director at Terrace Pharmaceuticals Private Limited (since 2023). The company operates in Pharma. Terrace Pharmaceuticals Private Limited reported revenue of ₹40.75 Cr (FY 2024).

DIN 10084815
Primary Designation Director
Industry Pharma
First Appointment 14 Mar 2023
Oldest Company Age 20 yrs
Largest company Terrace Pharmaceuticals Private Limited · ₹40.75 Cr (FY 2024)

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Director14 Mar 20232005₹40.75 Cr (FY 2024)Active

Board colleagues of Parveen Kumar

Directorship timeline

Open interactive timeline →
Terrace Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Parveen Kumar

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Parveen Kumar

Parveen Kumar currently holds 1 directorship: Terrace Pharmaceuticals Private Limited (Director, since 14 Mar 2023, revenue ₹40.75 Cr (FY 2024)).

Parveen Kumar was first appointed on 14 Mar 2023 as Director at Terrace Pharmaceuticals Private Limited.

The current boards of Parveen Kumar's companies include Gauri Shankar (Terrace Pharmaceuticals Private Limited), Robin Chopra (Terrace Pharmaceuticals Private Limited).

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available